Purpose: Diabetic Charcot arthropathy represents a major serious complication of diabetes, frequently culminating in nonunion and limb amputation. This study aimed to identify the risk factors of nonunion in patients with diabetic Charcot arthropathy. Materials and Methods: A retrospective analysis was conducted on 23 patients who received treatment for Charcot arthropathy of the Lisfranc joint at a single specialized medical center from January 2000 through September 2024. Eight patients underwent fusion surgery, and 15 underwent conservative treatment using a total contact cast. Follow-up observations were performed for at least 1 year, and joint fusion was evaluated. The primary risk factor examined was proper anatomical alignment assessed by Meary’s angle. The study also examined the treatment methods and various patient characteristics, including age, body weight index, blood sugar control (HbA1c), kidney function (eGFR), blood flow measurements (ABI and TBI), nerve function tests, smoking habits, hemodialysis treatment, and insulin use. Statistical analyses were performed using an independent t-test or Mann-Whitney U-test for the continuous variables and Fisher’s exact test for categorical variables. Results: Proper anatomical alignment showed a strong correlation with successful fusion and emerged as the most powerful predictor of treatment success (p=0.018). Statistical significance was also observed when Meary’s angle was analyzed as a continuous variable, which showed that a greater degree of malalignment was associated with a higher likelihood of nonunion (p=0.003). Other factors, including treatment method, patient age, body weight, blood sugar control, kidney function, blood flow measurements, nerve function tests, smoking habits, insulin use, and dialysis treatment, showed no meaningful relationship with fusion success. Conclusion For patients with Charcot arthropathy, proper anatomical alignment represents the most crucial factor determining successful bone fusion regardless of the treatment method. Therefore, establishing and preserving correct alignment greatly improves the joint fusion probability.

In the 2023 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Endometrial cancer: immune checkpoint inhibitor, antibody drug conjugates (ADCs), selective inhibitor of nuclear export, CDK4/6 inhibitors WEE1 inhibitor, poly (ADP-ribose) polymerase (PARP) inhibitors. 2) Cervical cancer: surgery in low-risk early-stage cervical cancer, therapy for locally advanced stage and advanced, metastatic, or recurrent setting; and 3) Ovarian cancer: immunotherapy, triplet therapies using immune checkpoint inhibitors along with antiangiogenic agents and PARP inhibitors, and ADCs. In 2023, the field of endometrial cancer treatment witnessed a landmark year, marked by several practice-changing outcomes with immune checkpoint inhibitors and the reliable efficacy of PARP inhibitors and ADCs.

In the 2023 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Endometrial cancer: immune checkpoint inhibitor, antibody drug conjugates (ADCs), selective inhibitor of nuclear export, CDK4/6 inhibitors WEE1 inhibitor, poly (ADP-ribose) polymerase (PARP) inhibitors. 2) Cervical cancer: surgery in low-risk early-stage cervical cancer, therapy for locally advanced stage and advanced, metastatic, or recurrent setting; and 3) Ovarian cancer: immunotherapy, triplet therapies using immune checkpoint inhibitors along with antiangiogenic agents and PARP inhibitors, and ADCs. In 2023, the field of endometrial cancer treatment witnessed a landmark year, marked by several practice-changing outcomes with immune checkpoint inhibitors and the reliable efficacy of PARP inhibitors and ADCs.

In the 2023 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Endometrial cancer: immune checkpoint inhibitor, antibody drug conjugates (ADCs), selective inhibitor of nuclear export, CDK4/6 inhibitors WEE1 inhibitor, poly (ADP-ribose) polymerase (PARP) inhibitors. 2) Cervical cancer: surgery in low-risk early-stage cervical cancer, therapy for locally advanced stage and advanced, metastatic, or recurrent setting; and 3) Ovarian cancer: immunotherapy, triplet therapies using immune checkpoint inhibitors along with antiangiogenic agents and PARP inhibitors, and ADCs. In 2023, the field of endometrial cancer treatment witnessed a landmark year, marked by several practice-changing outcomes with immune checkpoint inhibitors and the reliable efficacy of PARP inhibitors and ADCs.